Eli Lilly-backed Lycia fuels up on VC cash in a discovery drive toward protein degradation 2.0
Just weeks after nabbing a marquee alliance with Eli Lilly, the pharma giant has come back to support a $70 million B round for Lycia Therapeutics designed to fund the next stage of discovery at the protein degradation player.
Founder Versant Ventures also came back to add to the round, joining new investors Redmile Group, Cowen Healthcare Investments, Invus, RTW Investments, LP, Eli Lilly and Alexandria.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.